Reimbursement for diabetes medication is significantly increasing again in Belgium, a trend already observed in 2025 and accelerating into 2026. This development is a concern for experts and policymakers, as it further increases the pressure on the Belgian healthcare system, particularly the RIZIV/INAMI.
What's Happening
In 2025, nearly 130,000 patients in Belgium benefited from reimbursement for diabetes medications. These medications, while primarily intended for diabetes treatment, are also increasingly being used as weight loss products, contributing to the rising demand. The initial figures from the RIZIV/INAMI for early 2026 confirm this accelerating trend, indicating continued growth in both the number of users and the total expenditure for these treatments. This development has direct consequences for health insurance budgets and requires a thorough analysis of its causes and effects.
Impact of Newer Diabetes Treatments on Public Health
The growing popularity of certain diabetes medications as weight loss aids is a significant factor. This raises questions about the appropriate indication and use of these agents outside their original purpose, and how this affects availability and costs for diabetes patients. The Federal Agency for Medicines and Health Products (FAGG/AFMPS) is closely monitoring this situation to ensure the safety and effectiveness of these medications.
Background
The fight against diabetes has been a priority for Belgian public health for decades. Type 2 diabetes, often related to lifestyle factors, has a growing prevalence. Innovations in medication have led to more effective treatments, but also to higher costs. The dual function of some of these medicines as weight loss aids has further boosted demand, creating a complex problem for the RIZIV/INAMI and Belgian pharmacists. The Belgian government and the Minister of Public Health's cabinet are working on strategies to keep care affordable while ensuring the best treatments for patients who need them.
What This Means for Belgium
The continuous increase in reimbursements for diabetes medication has several implications for Belgium. Firstly, it places significant financial pressure on the RIZIV/INAMI budget, potentially leading to discussions about the redistribution of resources within the healthcare system. Secondly, it highlights the need for robust policies regarding medication management and oversight, to prevent misuse and direct resources towards the most urgent medical needs. Institutions like Sciensano play a crucial role in data collection and advising the government on public health. Finally, this trend may spark public discussion about preventive healthcare and the approach to obesity, as key factors in diabetes management. The role of general practitioners in prescribing this medication also becomes more important, given the broader context of use.